PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma.

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Poliovirus receptor (PVR, CD155) is upregulated in tumors, correlating with poor prognosis.
• PVR interacts with immune receptors like TIGIT, influencing adaptive and innate immunity.
• The prognostic role of PVR in multiple myeloma (MM) remains uninvestigated.

Purpose of the Study:

• To investigate the expression and prognostic significance of Poliovirus receptor (PVR) in multiple myeloma (MM).
• To explore the association between PVR expression and clinical parameters, disease stage, and survival outcomes in MM patients.

Main Methods:

• Immunohistochemistry, ELISA, qPCR, and flow cytometry were employed to assess PVR expression.
• Correlation analysis was performed between PVR levels and clinical data, including disease stage and survival.

Main Results:

• PVR was highly expressed in MM patients, with membrane PVR correlating with soluble PVR levels.
• PVR expression significantly associated with advanced MM stage, extramedullary disease, and higher bone marrow plasma cell percentage.
• High PVR expression correlated with shorter overall and progression-free survival, identifying it as an independent prognostic factor.

Conclusions:

• PVR expression is significantly associated with advanced disease characteristics in multiple myeloma.
• PVR serves as a potential independent prognostic biomarker for predicting poor survival outcomes in MM patients.